27.09.2010 • NewsLanxessPeople

Lanxess Announces Management Changes in 3 Business Units

There will be a change in management at three of the 13 business units of specialty chemicals company Lanxess. Dr. Hans-Georg Schmitt, head of the Basic Chemicals business unit (BAC), will retire as of Jan. 1. Schmitt has been in charge of Basic Chemicals since the formation of Lanxess.

Dr. Hubert Fink, currently head of the Semi-Crystalline Products business unit (SCP), will succeed Schmitt at the Basic Chemicals business unit at the turn of the year.

The successor to Dr. Fink as head of the SCP business unit is Dr. Michael Zobel, MBA. He will assume his new role as of Oct. 15. He is currently responsible for the Lanxess Ion Exchange Resins business unit (ION).

Dr. Zobel's position as head of ION will be taken over by Jean-Marc Vesselle at the same time. Vesselle is currently responsible for the global product management and strategic development of the business unit.

Company

Logo:

LANXESS Deutschland GmbH

Kennedyplatz 1
50569 Köln
Germany

Company contact







Interview

Fostering Innovation and Collaboration
Specialty Chemicals Distributor IMCD’s Strategy

Fostering Innovation and Collaboration

Valerie Diele-Braun, CEO of IMCD, shares her vision for sustainability, global expansions, and strategic direction in an exclusive CHEManager International interview.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
24.01.2025 • News

CEFIC Publishes 2024 Facts and Figures Report

CEFIC , the European Chemical Industry Council, has published its 2024 Facts & Figures report, which reinforces the need to take bold and urgent action to secure Europe’s industrial future, not only to implement the Green Deal but also to prevent further de-industrialization in Europe.

Photo
19.03.2025 • NewsInnovation

Data-Driven Enzyme Immobilization

Inseit, based in Bern, develops biocatalysts for industrial setups using enzyme immobilization and biocomputation. Addressing biotech and sustainability challenges, Inseit was selected for Venture Leaders Biotech and won two Nucleate accelerator prizes.

Photo
27.03.2025 • News

J&J to Invest $55 Billion in US Operations

US healthcare giant Johnson & Johnson (J&J) has unveiled plans to invest over $55 billion in the US over the next four years. This significant investment marks a 25% increase compared to the previous four years, the company said.

Photo
08.11.2024 • News

Future Prospects in Green Chemistry

The Discourse on Green Chemistry Interactive Pitch Competition, held on November 5, 2024, at Wiley's Berlin office as part of Berlin Science Week, showcased a range of innovative projects aimed at addressing critical environmental challenges.

Photo
29.10.2024 • News

GSK to Invest $800 Million in US Manufacturing Facility

British pharma company GlaxoSmithKline (GSK) plans to invest up to $800 million to expand drug substance and drug product manufacturing capabilities at the company’s US site in Marietta, Pennsylvania. The investment, which GSK said is its largest ever in US manufacturing, is expected to create more than 200 new jobs.